WO2000042003A1 - Benzenesulfonamide derivatives and their use as mek inhibitors - Google Patents
Benzenesulfonamide derivatives and their use as mek inhibitors Download PDFInfo
- Publication number
- WO2000042003A1 WO2000042003A1 PCT/US1999/030435 US9930435W WO0042003A1 WO 2000042003 A1 WO2000042003 A1 WO 2000042003A1 US 9930435 W US9930435 W US 9930435W WO 0042003 A1 WO0042003 A1 WO 0042003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iodo
- phenylamino
- benzamide
- sulfamoyl
- difluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- the invention relates to benzenesulfonamides and derivatives thereof.
- BACKGROUND MEK enzymes are dual specificity kinases involved in, for example, immunomodulation, inflammation, and proliferative diseases such as cancer and restenosis.
- Proliferative diseases are caused by a defect in the intracellular signaling system, or the signal transduction mechanism of certain proteins. Defects include a change either in the intrinsic activity or in the cellular concentration of one or more signaling proteins in the signaling cascade .
- the cell may produce a growth factor that binds to its own receptors, resulting in an autocrine loop, which continually stimulates proliferation. Mutations or overexpression of intracellular signaling proteins can lead to spurious mitogenic signals within the cell.
- Ras a G-protein that is activated when bound to GTP, and inactivated when bound to GDP.
- This signal is an absolute prerequisite for proliferation in most cell types. Defects in this signaling system, especially in the deactivation of the Ras-GTP complex, are common in cancers, and lead to the signaling cascade below Ras being chronically activated. Activated Ras leads in turn to the activation of a cascade of serine/threonine kinases.
- MAP kinase Activation of MAP kinase by mitogens appears to be essential for proliferation; constitutive activation of this kinase is sufficient to induce cellular transformation.
- Blockade of downstream Ras signaling for example by use of a dominant negative Raf-1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants.
- Ras is not itself a protein kinase, it participates in the activation of Raf and other kinases, most likely through a phosphorylation mechanism.
- Raf and other kinases phosphorylate MEK on two closely adjacent serine residues, s218 and S 2 22 j n the case of MEK-1 , which are the prerequisite for activation of MEK as a kinase.
- MEK in turn phosphorylates MAP kinase on both a tyrosine, Y 1 85 anc
- MAP kinase phosphorylations are mitogenically activating for the target protein, such as a kinase, a transcription factor, or another cellular protein.
- target protein such as a kinase, a transcription factor, or another cellular protein.
- other kinases activate MEK, and MEK itself appears to be a signal integrating kinase.
- Current understanding is that MEK is highly specific for the phosphorylation of MAP kinase.
- no substrate for MEK other than the MAP kinase ERK, has been demonstrated to date and MEK does not phosphorylate peptides based on the MAP kinase phosphorylation sequence, or even phosphorylate denatured MAP kinase.
- MEK also appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Both this requirement and the unusual specificity of MEK are suggestive that it may have enough difference in its mechanism of action to other protein kinases that selective inhibitors of MEK, possibly operating through allosteric mechanisms rather than through the usual blockade of the ATP binding site, may be found.
- the invention features a compound having the formula (I) below:
- W is OR-,, NR2OR1, NR A R B , NR 2 NR A R B , or NR 2 (CH 2 ) 2-4 NR A R B .
- RI is H, C ⁇ -8 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, C 3-8 cycloalkyl, phenyl, (phenyl)C - alkyl, (phenyl)C 3- alkenyl, (phenyl)C 3- alkynyl, (C 3-8 cycloalkyl)-
- RB- R2 is H, phenyl, C 1 ⁇ alkyl, C 3-4 alkenyl C 3-8 alkynyl, C 3-8 cycloalkyl, or (C 3-8 cycloalkyl)C 1- alkyl.
- R A is H, C ⁇ -6 alkyl, C 3 . 8 alkenyl, C 3-8 alkynyl, C 3- s cycloalkyl, phenyl, (C 3-8 cycloalkyl)C 1. alkyl, (C 3-8 cycloalkyl)C 3- alkenyl, (C 3-8 cycloalkyl)C 3-4 alkynyl, C 3-8 heterocyclic radical, (C 3- s heterocyclic radical)C ⁇ - alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C ⁇ -4 alkyl, (aminosulfonyl)C 1 .
- R B is H, C 1-8 alkyl, C 3-8 alkenyl, C 3 _ 8 alkynyl, C 3-8 cycloalkyl, or C 6 -8 aryl.
- R 3 is H, F, Cl, Br, or NO 2 .
- R 4 is H or F.
- R 5 is H, methyl or Cl.
- R 6 is H, C 1- alkyl, hydroxyethyl, hydroxypropyl, (CH 2 ) 2- (NR C RD), phenyl, 2-pyridyl, 3-pyridyl, 4- pyridyl or CH 2 Ar, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.
- R 7 is H, C- alkyl, hydroxyethyl, hydroxypropyl, (CH 2 ) 2-4 (NR C RD), phenyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, or CH 2 Ar', where Ar' is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.
- Each of Re and R D is independently selected from H, C 1-6 alkyl, C 3-4 alkenyl, C 3- 4 alkynyl, C 3- ⁇ cycloalkyl, C 3 . ⁇ heterocyclic radical, and phenyl.
- NRCRD can also be selected from morpholinyl, piperazinyl, pyrrolidinyl, or piperadinyl.
- Each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C 1 alkyl, C 3-6 cycloalkyl, C 2- alkenyl, C 2-4 alkynyl, phenyl, hydroxy, amino, (amino)sulfonyl, and NO 2 , wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C 1-2 alkyl, hydroxy, amino, and NO 2 .
- the invention also features pharmaceutically acceptable salts and C ⁇ -7 esters thereof.
- Preferred compounds include PD 297764, 3,4-Difluoro-2-(4-iodo- phenylamino)-N-methoxy-5-(4-pyridin-2-yl-piperazine-1-sulfonyl)-benzamide; PD 297765, N-Allyloxy-3,4-difluoro-2-(4-iodo-phenylamino)-5-(4-methyl- piperazine-1-sulfonyl)-benzamide; PD297766, N-Allyloxy-5-[(2-diethylamino- ethyl)-methyl-sulfamoyl]-3,4-difluoro-2-(4-iodo-phenylamino)-benzamide; PD297767, N-Allyloxy-5-[(3-dimethylamino-propyl)-methyl-sulfamoyl]-3,4-difluoro- 2-(4-
- PD297772 5-[Benzyl-(2-dimethylamino-ethyl)-sulfamoyl]-N-cyclopropylmethoxy- 3,4-difluoro-2-(4-iodo-phenylamino)-benzamide; PD297773, 3,4-Difluoro-2-(4- iodo-2-methyi-phenylamino)-N-methoxy-5-(4-pyridin-2-yl-piperazine-1-sulfonyl)- benzamide; and PD297774, 1-[5-Allyloxycarbamoyl-2,3-difluoro-4-(4-iodo-2- methyl-phenylamino)-benzenesulfonyl]-piperidine-3-carboxylic acid amide.
- the invention also relates to a pharmaceutical composition including (a) a compound of formula (I) and (b) a pharmaceutically-accept
- the invention further relates to a method for treating proliferative diseases, such as cancer, restenosis, psoriasis, autoimmune disease, and atherosclerosis.
- proliferative diseases such as cancer, restenosis, psoriasis, autoimmune disease, and atherosclerosis.
- Other aspects of the invention include methods for treating MEK-related
- cancers include colorectal, cervical, breast, ovarian, brain, acute leukemia, gastric, non-small cell lung, pancreatic and renal cancer.
- Further aspects of the invention include methods for treating or reducing the symptoms of xenograft (cell(s), skin, limb, organ or bone marrow transplant) rejection, osteoarthritis, rheumatoid arthritis, cystic fibrosis, complications of diabetes (including diabetic retinopathy and diabetic nephropathy), hepatomegaly, cardiomegaly, stroke (such as acute focal ischemic stroke and global cerebral ischemia), heart failure, septic shock, asthma, and Alzheimer's disease.
- Compounds of the invention are also useful as antiviral agents for treating viral infections such as HIV, hepatitis B virus (HBV), human papilloma virus (HPV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV).
- HBV hepatitis B virus
- HPV human papilloma virus
- CMV cytomegalovirus
- EBV Epstein-Barr virus
- the invention also features methods of combination therapy, such as a method for treating cancer, wherein the method further includes providing radiation therapy or chemotherapy, for example, with mitotic inhibitors such as a taxane or a vinca alkaloid.
- mitotic inhibitors include paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine.
- Other therapeutic combinations include a MEK inhibitor of the invention and an anticancer agent such as cisplatin, 5-fluorouracil or 5-fluoro-2-4(1 H,3H)-pyrimidinedione (5FU), flutamide, and gemcitabine.
- the chemotherapy or radiation therapy may be administered before, concurrently, or after the administration of a disclosed compound according to the needs of the patient.
- the invention also features synthetic methods and synthetic intermediates disclosed herein.
- the invention features benzenesulfonamide compounds, pharmaceutical compositions thereof, and methods of using such compounds and compositions.
- the compounds are MEK inhibitors.
- MEK inhibition assays include the cascade assay for inhibitors of MAP kinase pathway described at column 6, line 36 to column 7, line 4 of U.S. Patent Number 5,525,625 and the in vitro MEK assay at column 7, lines 4-27 of the same patent, the entire disclosure of which is incorporated by reference (see also Examples 5-10 below).
- Alkyl groups include aliphatic (i.e., hydrocarbyl or hydrocarbon radical structures containing hydrogen and carbon atoms) with a free valence. Alkyl groups are understood to include straight chain and branched structures. Examples include methyl, ethyl, propyi, isopropyl, butyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, 2,3-dimethylpropyl, hexyl, 2,3-dimethylhexyl, 1 ,1-dimethylpentyl, heptyl, and octyl. Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Alkyl groups can be substituted with 1 , 2, 3 or more substituents which are independently selected from halo (fluoro, chloro, bromo, or iodo), hydroxy, amino, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, arylalkyloxy, heterocyclic radical, and (heterocyclic radical)oxy.
- substituents are independently selected from halo (fluoro, chloro, bromo, or iodo), hydroxy, amino, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, arylalkyloxy, heterocyclic radical, and (heterocyclic radical)oxy.
- Specific examples include fluoromethyl, hydroxyethyl, 2,3-dihydroxyethyl, (2- or 3-furanyl)methyl, cyclopropylmethyl, benzyloxyethyl, (3-pyhdinyl)methyl, (2- or 3-furanyi)methyl, (2- thienyl)ethyl, hydroxypropyl, aminocyclohexyl, 2-dimethylaminobutyl, methoxymethyl, ⁇ -py rid inylethy I , diethylaminoethyl, and cyclobutylmethyl.
- Alkenyl groups are analogous to alkyl groups, but have at least one double bond (two adjacent sp 2 carbon atoms). Depending on the placement of a double bond and substituents, if any, the geometry of the double bond may be Mais (E), or sixteen (Z), cis, or trans. Similarly, alkynyl groups have at least one triple bond (two adjacent sp carbon atoms). Unsaturated alkenyl or alkynyl groups may have one or more double or triple bonds, respectively, or a mixture thereof; like alkyl groups, unsaturated groups may be straight chain or branched, and they may be substituted as described both above for alkyl groups and throughout the disclosure by example.
- alkenyls, alkynyls, and substituted forms include cis-2-butenyl, trans-2-butenyl, 3-butynyl, 3-phenyl-2- propynyl, 3-(2'-fluorophenyl)-2-propynyl, 3-methyl(5-phenyl)-4-pentynyl, 2- hydroxy-2-propynyl, 2-methyl-2-propynyl, 2-propenyl, 4-hydroxy-3-butynyl, 3-(3- fluorophenyl)-2-propynyl, and 2-methyl-2-propenyl.
- alkenyls and alkynyls can be C 2-4 or C 2 . 8 , and are preferably C 3-4 or C 3- s.
- substituted hydrocarbon radicals include hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, and corresponding forms for the prefixes amino-, halo- (e.g., fluoro-, chloro-, or bromo-), nitro-, alkyl-, phenyl-, cycloalkyl- and so on, or combinations of substituents.
- halo- e.g., fluoro-, chloro-, or bromo-
- substituted alkyls include hydroxyalkyl, aminoalkyl, nitroalkyl, haloalkyl, alkylalkyl (branched alkyls, such as methylpentyl), (cycloalkyl)alkyl, phenylalkyl, alkoxy, alkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryloxyalkyl, arylalkyloxyalkyl, (heterocyclic radical)alkyl, and (heterocyclic radical)oxyalkyl.
- Ri thus includes hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminocycloalkyl, aminoaryl, alkylalkenyl, (alkylaryl)alkyl, (haloaryl)alkyl, (hydroxyaryl)alkynyl, and so forth.
- R A includes hydroxyalkyl and aminoaryl
- R B includes hydroxyalkyl, aminoalkyl, and hydroxyalkyl(heterocyclic radical)alkyl.
- Heterocyclic radicals which include but are not limited to heteroaryls, include: furyl, oxazolyl, isoxazoiyl, thiophenyl, thiazolyl, pyrrolyl, imidazolyl, 1 ,3,4- triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, indolyl, and their nonaromatic counterparts.
- heterocyclic radicals include piperidyl, quinolyl, isothiazolyl, piperidinyi, morphoiinyl, piperazinyl, tetrahydrofuryl, tetrahydropyrrolyl, pyrrolidinyl, octahydroindolyl, octahydrobenzothiofuranyl, and octahydrobenzofuranyl.
- Selective MEK 1 or MEK 2 inhibitors are those compounds which inhibit the MEK 1 or MEK 2 enzymes, respectively, without substantially inhibiting other enzymes such as MKK3, PKC, Cdk2A, phosphorylase kinase, EGF, and PDGF receptor kinases, and C-src.
- a selective MEK 1 or MEK 2 inhibitor has an IC 5 o for MEK 1 or MEK 2 that is at least one-fiftieth (1/50) that of its IC 50 for one of the above-named other enzymes.
- a selective inhibitor has an IC 50 that is at least 1/100, more preferably 1/500, and even more preferably 1/1000, 1/5000, or less than that of its IC 50 or one or more of the above-named enzymes.
- Examples of compounds of formula (I) have structures wherein: (a) the sulfamoyl group is meta to VV(CO)- and para to the bridging NH; (b) the sulfamoyl group is para to W (CO)- and meta to the bridging NH; (c) R 4 is fluoro; (d) R 3 is fluoro; (e) R 3 is H; (f) W is OH; (g) W is NR 2 OR ⁇ ; (h) each of R 3 and R 4 is fluoro; (i) Ri has at least one hydroxy substituent; (k) Ri is H, methyl, ethyl, propyl, isopropyl, isobutyl, benzyl, phenethyl, allyl, C 2-5 alkenyl, C 2 - ⁇ alkynyl, C 3 .6 cycloalkyl, (C 3-5 cycloalkyl)C ⁇ -2 alkyl, (C 3-5
- R B is H; or where R B is methyl and R A is phenyl; (o) R 7 is (CH 2 ) 2-4 (NR C RD); (p) NRCRD is selected from morpholinyl, piperazinyl, pyrrolidinyl, or piperadinyl; (q) R c is methyl, ethyl, hydroxyethyl, or hydroxypropyl; (r) R 5 is methyl or chloro; (s) RD is methyl, ethyl, hydroxyethyl, or hydroxypropyl; (t) or combinations thereof, such as wherein each of
- Ri, R 2 , R A , R B , Rc, or RD is an alkenyl or alkynyl group
- the double or triple bond, respectively is not adjacent the point of attachment.
- W is NR 2 OR 1
- R 2 is preferably prop-2-ynyl, or but-2 or 3-enyl, and less preferably prop-1-ynyl or but-1-enyl.
- Examples of compounds of formula (I) include: 2-(2-chloro-4-iodo- phenylamino)-4-sulfamoyi-benzoic acid; 2-(2-chloro-4-iodo-phenylamino)-N- hydroxy-4-sulfamoyl-benzamide; 2-(2-chloro-4-iodo-phenylamino)-N- cyclopropylmethoxy-4-sulfamoyl-benzamide; 2-(2-chloro-4-iodo-phenylamino)-4- (2-morpholin-4-yl-ethylsulfamoyl)-benzoic acid; 2-(2-chloro-4-iodo-phenylamino)- N-hydroxy-4-(2-morpholin-4-yl-ethylsulfamoyl)-benzamide; 2-(2-chloro-4-iodo- phenylamino)-N-cyclopropylmeth
- Additional examples include 5-(bis-pyridin-3-ylmethyl-sulfamoyl)-3,4- difluoro-2-(4-iodo-phenylamino)-benzoic acid; 5-(bis-pyridin-3-ylmethyl- sulfamoyl)-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-phenylamino)- benzamide; N-cyciopropylmethoxy-3,4-difluoro-2-(4-iodo-phenylamino)-5-(methyl- pyridin-3-ylmethyl-sulfamoyl)-benzamide; N-cyclopropylmethoxy-3,4-difluoro-2-(4- iodo-phenylamino)-5-[(py din-3-ylmethyl)-sulfamoyl]-benzamide; N- cyclopropylmeth
- Particularly preferred compounds include: PD 298458, N-Allyloxy-2-(2- chloro-4-iodo-phenylamino)-3,4-difluoro-5-(4-methyl-piperazine-1-sulfonyl)- benzamide; PD 298459, N-Allyloxy-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro- 5-(methyl-phenyl-sulfamoyl)-benzamide; PD 298460, 5-(Allyl-methyl-sulfamoyl)- N-allyloxy-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzamide; PD 298463, 1-[5-Allyloxycarbamoyl-4-(2-chloro-4-iodo-phenylamino)-2,3-difluoro- benzenesulfonyl]
- the disclosed compounds can be synthesized according to the following four Schemes, or variants thereof. These synthetic strategies, which are suitable for conventional or combinatorial synthetic methods, are further exemplified in Examples 1-4 below.
- Additional compounds within claim 1 can be made with the following amine reagents. The corresponding CAS number is provided.
- the appropriate hydroxylamine hydrochloride solution (0.05 mmol, 1 mL) was added to a 2-dram vial, and each vial was treated with 5- chlorosulfonyl-2,3,4-trifluoro-benzoyl chloride solution (0.05 mmol, 1 mL). After 20 minutes the appropriate amine solution (0.05 mmol, 1 mL) was added sequentially. After a further 20 minutes the vials were treated with the solution of 4-iodoaniline (0.055 mmol, 1 mL). The vials were capped and shaken overnight at room temperature. The reactions were quenched with 1 mL of a 1 M aqueous ammonium chloride solution.
- the vials were concentrated to dryness under a stream of nitrogen and purified by reverse phase HPLC using a 30x100 mm YMC ODS-A (C18) column.
- the mobile phase was acetonitrile/water (both with 0.05% trifluoroacetic acid) at 25 mUmin and a linear gradient of 10-100% over 6.5 min and then 3.5 min at 100%, detection was at 214 nm.
- the vials were treated with the solution of 4-iodo-2-methylaniiine (0.05 mmol, 0.91 mL).
- the vials were capped and shaken overnight at room temperature.
- the reactions were quenched with 1 mL of a 1 M aqueous ammonium chloride solution.
- the vials were concentrated to dryness under a stream of nitrogen and purified by reverse phase HPLC using a 30x100 mm YMC ODS-A (C18) column.
- the mobile phase was acetonitrile/water (both with 0.05% thfluoroacetic acid) at 25 mlJmin and a linear gradient of 10-100% over 6.5 min and then 3.5 min at 100%, detection was at 214 nm.
- the vials were treated with the solution of 2-chloro-4-iodoaniline (0.05 mmol, 0.91 mL). The vials were capped and shaken overnight at room temperature. The reactions were quenched with 1 mL of a 1 M aqueous ammonium chloride solution. The vials were concentrated to dryness under a stream of nitrogen and purified by reverse phase HPLC using a 30x100 mm YMC ODS-A (C18) column. The mobile phase was acetonitrile/water (both with 0.05% thfluoroacetic acid) at 25 mlJmin and a linear gradient of 10-100% over 6.5 min and then 3.5 min at 100%, detection was at 214 nm.
- compositions are useful as both prophylactic and therapeutic treatments for diseases or conditions as provided in the Summary section, as well as diseases or conditions modulated by the MEK cascade.
- diseases or conditions modulated by the MEK cascade examples include stroke, heart failure, osteoarthritis, rheumatoid arthritis, organ transplant rejection, and a variety of tumors such as ovarian, lung, pancreatic, brain, prostatic, renal, and colorectal.
- an effective amount will be between 0.1 and 1000 mg/kg per day, preferably between 1 and 300 mg/kg body weight, and daily dosages will be between 10 and 5000 mg for an adult subject of normal weight.
- Capsules, tablets or other formulations may be of between 5 and 200 mg, such as 10, 15, 25, 35, 50 mg, 60 mg, and 100 mg and can be administered according to the disclosed methods.
- Dosage unit forms include tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for subdivision into individual doses. Dosage unit forms can also be adapted for various methods of administration, including controlled release formulations, such as subcutaneous implants. Administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal, intravesical, local (drops, powders, ointments, gels, or cream), and by inhalation (a buccal or nasal spray).
- Parenteral formulations include pharmaceutically acceptable aqueous or nonaqueous solutions, dispersion, suspensions, emulsions, and sterile powders for the preparation thereof.
- carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size.
- Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption acccelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propeilants.
- Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents. 3. Related compounds
- the invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms.
- Pharmaceutically acceptable salts, esters, and amides include carboxylate salts (e.g., C ⁇ -8 alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic), amino acid addition salts, esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective, and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
- carboxylate salts e.g., C ⁇ -8 alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic
- amino acid addition salts esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective, and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
- Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate.
- alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
- alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium
- non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
- amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
- Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C 1-6 alkyl amines and secondary di (C ⁇ -6 alkyl) amines.
- Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms.
- Preferred amides are derived from ammonia, C 1-3 alkyl primary amines, and di (C ⁇ -2 aikyl)amines.
- Representative pharmaceutically acceptable esters of the invention include C ⁇ -7 alkyl, C 5-7 cycloalkyl, phenyl, and phenyl(C ⁇ . 6 )alkyl esters.
- Preferred esters include methyl esters.
- the invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.
- one or more functional groups e.g., hydroxyl, amino, or carboxyl
- Hydroxyl protecting groups include: ethers, esters, and protection for 1 ,2- and 1 ,3-diols.
- the ether protecting groups include: methyl, substituted methyl ethers, substituted ethyl ethers, substituted benzyl ethers, silyl ethers and conversion of silyl ethers to other functional groups. Substituted Methyl Ethers
- Substituted methyl ethers include: methoxymethyl, methylthiomethyl, f-utylthiomethyl, (phenyldimethylsilyl) methoxymethyl, benzyloxymethyl, p-ethoxybenzyloxymethyl, (4-methoxyphenoxy) methyl, guaiacolmethyl, f-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloro- ethoxy)methyl, 2-(trimethylsilyl)- ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydro-pyranyl, tetrahydrothiopyranyl, 1 -methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydro- thiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-d
- Substituted Ethyl Ethers include: 1-ethoxyethyl, 1-(2,chloroethoxy)ethyl, 1 -methyl- 1 -methoxyethyl , 1 -methyl-1 -benzyloxyethyl , 1 -methyl- 1 -benzyloxy-2- fluoroethyl, 2,2,2-trichloroethyl, 2-trimethy Isiiyethyl , 2-(phenylselenyl)ethyl, f-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyi, and benzyl.
- Substituted Benzyl Ethers include: p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenyibenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl ⁇ /-oxido, diphenylmethyl, p, p -dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, ⁇ -naphthyldiphenyl- methyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri-(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-tris(
- Silyl Ethers Silyl ethers include: trimethylsilyi, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, f-butyldimethylsilyl, -butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethyisilyl, and f-butylmethoxy- phenylsilyl.
- Esters protecting groups include: esters, carbonates, assisted cleavage, miscellaneous esters, and sulfonates. Esters
- protective esters include: formate, benzoylformate, acetate, chloroacetate, dichloroacetate, t chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P- phenylacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4- (ethylenedithio) pentanoate, pivaloate, adamantoate, crotonate, 4- methoxycrotonate, benzoate, p-phenylbenzoate, and 2,4,6-trimethylbenzoate (mesitoate).
- Carbonates include: methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl) ethyl, 2-(phenylsulfonyl) ethyl, 2-(triphenylphosphonio) ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.
- Assisted Cleavage 2-(trimethylsilyl) ethyl, 2-(phenylsulfonyl) ethyl, 2-(triphenylphosphonio) ethyl, isobutyl, vinyl, allyl, p-nitropheny
- assisted cleavage protecting groups include: 2-iodobenzoate, 4- azido-butyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl) benzoate, 2- formylbenzene-sulfonate, 2-(methylthiomethoxy) ethyl carbonate, 4- (methylthiomethoxymethyl) benzoate, and 2-(methylthiomethoxymethyl) benzoate.
- miscellaneous esters include: 2,6-dichloro-4- methylphenoxyacetate, 2,6-dichloro-4-(1 ,1 ,3,3-tetramethylbutyl) phenoxyacetate, 2,4-bis(1 ,1-dimethylpropyl) phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate (tigloate), o-(methoxycarbonyl) benzoate, p-P-benzoate, ⁇ -naphthoate, nitrate, alkyl N,N,N N '-tetramethyl- phosphorodiamidate, ⁇ /-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate.
- Protective sulfates includes: suifate, methanesulfonate(mesylate), benzylsulfonate, and tosyiate.
- the protection for 1 ,2 and 1 ,3-diois group includes: cyclic acetals and ketals, cyclic ortho esters, and silyl derivatives.
- Cyclic Acetals and Ketals include: methylene, ethylidene, 1- -butylethylidene, 1-phenylethylidene, (4-methoxyphenyl) ethylidene, 2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4- dimethoxybenzylidene, and 2-nitrobenzylidene.
- Cyclic ortho esters include: methoxymethylene, ethoxymethylene, dimethoxy- methylene, 1-methoxyethylidene, 1-ethoxyethylidine, 1 ,2-dimethoxyethylidene, ⁇ -methoxybenzylidene, 1-(A/, ⁇ /-dimethylamino)ethylidene derivative, -(N,N- dimethylamino) benzylidene derivative, and 2-oxacyclopentylidene.
- Ester protecting groups include: esters, substituted methyl esters, 2-substituted ethyl esters, substituted benzyl esters, silyl esters, activated esters, miscellaneous derivatives, and stannyl esters.
- Substituted Methyl Esters include: 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2- (trimethylsilyl)ethoxy-methyl, benzyloxymethyl, phenacyl, p-bromophenacyl, ⁇ - methylphenacyl, p-methoxyphenacyl, carboxamidomethyl, and N- phthaiimidomethyl.
- 2-Substituted Ethyl Esters include: 2,2,2-trichloroethyl, 2-haloethyl, l-chloroalkyl, 2-(trimethylsily)ethyl, 2-methylthioethyl, 1 ,3-dithianyl-2-methyl, 2(p- nitrophenylsulfenyl)-ethyl, 2-(p-toluenesulfonyl)ethyl, 2-(2'-pyridyl)ethyl, 2- (diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, f-butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsily)-2-buten-1-yl, cinnamyl, -methylcinnamyl, phenyl, p-(methylmer
- Substituted Benzyl esters include: triphenylmethyl, diphenylmethyl, bis(o-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl, 1 -pyrenylmethyl, 2-(trifluoromethyl)-6-chromylmethyl, 2,4,6- trimethylbenzyl, p-bromobenzyl, o-nitrobenzyl, p-nitrobenzyl, p-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl, piperonyl, and 4-P- benzyl.
- Silyl esters include: trimethylsilyl, triethylsilyl, r-butyldimethylsilyl, / ' - propyldimethylsilyl, phenyldimethylsilyl, and di- -butylmethylsilyl.
- Miscellaneous derivatives includes: oxazoles, 2-alkyl-1 ,3-oxazolines, 4-alkyl-5- oxo-1, 3-oxazolidines, 5-alkyl-4-oxo-1 ,3-dioxolanes, ortho esters, phenyl group, and pentaaminocobalt(lll) complex.
- Stannyl Esters
- stannyl esters include: triethylstannyl and th-n-butylstannyl.
- Amides include: N,N -dimethyl, pyrrolidinyl, piperidinyl, 5,6- dihydrophenanthhdinyl, o-nitroanilides, ⁇ /-7-nitroindolyl, /V-8-nitro-1 ,2,3,4- tetrahydroquinolyl, and p-P-benzenesulfonamides.
- Hydrazides include: ⁇ /-phenyl, N,N '-diisopropyl and other dialkyl hydrazides.
- Carbamates include: carbamates, substituted ethyl, assisted cleavage, photolytic cleavage, urea-type derivatives, and miscellaneous carbamates.
- Carbamates Carbamates include: methyl and ethyl, 9-fluorenylmethyl, 9-(2- sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-d -butyl-[9-(10, 10- dioxo-10,10,10,10-tetrahydro- thioxanthyl)]methyl, and 4-methoxyphenacyl.
- Substituted Ethyl protective groups include: 2,2,2-trichloroethyl, 2- trimethy Isilylethyl , 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1 ,1-dimethyl-2- haloethyl, 1 ,1dimethyl-2,2-dibromoethyl, 1 ,1-dimethyl-2,2,2-trichloroethyl, 1- methyl-1-(4-biphenylyl)ethyl, 1-(3,5-di- -butylphenyl)-1-methylethyl, 2-(2'-and 4'- pyridyl)ethyl, 2-( ⁇ /,A/-icyclohexylcarboxamido)- ethyl, f-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylally
- Assisted Cleavage Protection via assisted cleavage includes: 2-methylthioethyl, 2- methylsulfonylethyl, 2-(p-toluenesulfonyl)ethyl, [2-(1 ,3-dithianyl)]methyl, 4- methylthiophenyl, 2,4-dimethyl-thiophenyl, 2-phosphonioethyl, 2- triphenylphosphonioisopropyl, 1 ,1-dimethyl-2cyanoethyl, m-chloro-p- acyloxybenzyl, p-(dihydroxyboryl)benzyl, 5-benzisoxazolyl-methyl, and 2- (trifluoromethyl)-6-chromonylmethyl.
- Photolytic Cleavage uses groups such as: m-nitrophenyl, 3,5- dimethoxybenzyl, o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(o- nitrophenyl)methyl.
- Urea-Type Derivatives examples include: phenothiazinyl-(10)-carbonyl derivative, N '-p-toluenesulfonylaminocarbonyl, and N '-phenylaminothiocarbonyl.
- miscellaneous carbamates include: f-amyl, S-benzyl thiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, p-decyloxy-benzyl, diisopropyimethyl, 2,2-dimethoxy- carbonylvinyl, o-( ⁇ /, ⁇ /-dimethyl-carboxamido)-benzyl, 1 ,1-dimethyl-3( ⁇ /, ⁇ /- dimethylcarboxamido)propyl, 1 ,1-dimethyl-propynyl, di(2-pyridyl)methyl, 2- furanylmethyl, 2-iodoethyl, isobomyl, isobutyl, isonicotinyl, p(p - methoxyphenylazo)benzyl, 1 -methylcyclo
- Amides Amides includes: ⁇ /-formyl, ⁇ /-acetyl, A/-chloroacetyl, ⁇ /-trichloroacetyl,
- Assisted cleavage groups include: ⁇ /-o-nitrophenylacetyl, N-o- nitrophenoxyacetyl, ⁇ /-acetoacetyl, (tV-dithiobenzyloxycarbonylamino)acetyl, ⁇ /-3- (p-hydroxphenyl) propionyl, ⁇ /-3-(o-nitrophenyl)propionyl, ⁇ /-2-methyl-2-(o- nitrophenoxy)propionyl, ⁇ /-2-methyl-2-(o-phenylazophenoxy)propionyl, ⁇ /-4- chlorobutyryl, ⁇ /-3-methyl-3-nitrobutyryl, ⁇ /-o-nitrocinnamoyl, ⁇ /-acetylmethionine derivative, ⁇ /-o-nitrobenzoyl, ⁇ /-o-(benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3- oxazolin-2-one
- Cyclic imide derivatives include: ⁇ /-phthaiimide, ⁇ /-dithiasuccinoyl, ⁇ /-2,3-diphenyl-maleoyl, ⁇ /-2,5-dimethylpyrrolyl,
- Protective groups for - NH include: ⁇ /-alkyl and ⁇ /-aryl amines, imine derivatives, enamine derivatives, and ⁇ /-hetero atom derivatives (such as ⁇ /-metal, N-N, N-P, N-Si, and N-S), ⁇ /-sulfenyl, and ⁇ /-suifonyl.
- ⁇ /-alkyl and ⁇ /-aryl amines include: ⁇ /-methyl, ⁇ /-allyl, ⁇ /-[2-(trimethylsilyl)ethoxyl]- methyl, ⁇ /-3-acetoxypropyl, ⁇ /-(1 -isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), quaternary ammonium salts, ⁇ /-benzyl, ⁇ /-di(4-methoxyphenyl)methyl, ⁇ /-5-dibenzosuberyl, ⁇ /-triphenylmethyl, ⁇ /-(4-methoxyphenyl)diphenylmethyl,
- Imine derivatives include: ⁇ /-1 ,1-dimethylthiomethylene, ⁇ /-benzylidene, ⁇ /-p-methoxybenzylidene, ⁇ /-diphenylmethylene, ⁇ /-[(2-pyridyl)mesityl]methylene,
- Enamine Derivatives An example of an enamine derivative is ⁇ /-(5,5-dimethyl-3-oxo-1-cyclohexenyl). ⁇ /-Hetero Atom Derivatives
- ⁇ /-metal derivatives include: ⁇ /-borane derivatives, ⁇ /-diphenylborinic acid derivative, ⁇ /-[phenyl(pentacarbonylchromium- or -tungsten)]carbenyl, and
- N-N derivatives include: ⁇ /-nitro, ⁇ /-nitroso, and ⁇ /-oxide.
- N-P derivatives include:
- ⁇ /-sulfenyl derivatives examples include: ⁇ /-benzenesulfenyl,
- ⁇ /-sulfonyl derivatives include: ⁇ /-p-toluenesulfonyl, ⁇ /-benzenesulfonyl, N- 2,3,6-trimethyl- 4-methoxybenzenesulfonyl, ⁇ /-2,4,6-trimethoxybenzenesulfonyl, ⁇ /-2,6-dimethyl-4-methoxy-benzenesulfonyl, ⁇ /-pentamethylbenzenesulfonyl, N- 2,3,5,6-tetramethyl-4-methoxybenzene- sulfonyl, ⁇ /-4-methoxybenzenesulfonyl, ⁇ /-2,4,6-trimethylbenzenesulfonyl, ⁇ /-2,6-dimethoxy- 4-methylbenzenesuifonyl, N- 2,2,5,7,8-pentamethylchroman-6-sulfonyl, ⁇ /-me
- Disclosed compounds which are masked or protected may be prodrugs, compounds metabolized or otherwise transformed in vivo to yield a disclosed compound, e.g., transiently during metabolism.
- This transformation may be a hydrolysis or oxidation which results from contact with a bodily fluid such as blood, or the action of acids, or liver, gastrointestinal, or other enzymes.
- Step a Preparation of 1-dimethylsulfamoyl-2,3,4-trifluorobenzene
- a gently stirring solution comprised of 2,3,4-trifluorobenzenesulfonyl chloride (5.70 g, 0.0247 mol) in 1 ,2-dichloroethane (200 ml) was introduced by bubbling gaseous anhydrous dimethylamine.
- the mixture became cloudy after several minutes and was subsequently washed with water (200 ml), 6 N aqueous hydrochloric acid (200 ml), brine (200 ml), was dried over anhydrous magnesium sulfate, and was concentrated in vacuo to obtain a yellow oil.
- the crude product was purified by flash chromatography. Elution with dichloromethane afforded
- Step b Preparation of 5-dimethylsulfamoyl-2,3,4-trifluoro-benzoic acid
- the cold bath was removed and the reaction mixture warmed to ambient temperature over one hour.
- the mixture was then carefully quenched with 10 % aqueous hydrochloric acid (200 ml).
- the layers were separated.
- the organic phase was extracted twice (200, 100 ml portions) with 10 % (wt.) aqueous sodium hydroxide.
- the combined aqueous alkaline extracts were treated with concentrated aqueous hydrochloric acid (100 ml) to pH 0. A white precipitate formed.
- the suspension was allowed to cool, then was extracted with diethyl ether (600 ml).
- Step c Preparation of 5-dimethylsulfamoyl-2.3,4-thfluoro-benzoic acid methyl ester
- Step d Preparation of 2-(2-chloro-4-iodo-phenylamino)-5-dimethylsulfamoyl-3,4- difluoro-benzoic acid methyl ester
- Step a Preparation of 1- ⁇ /s-(4-methoxybenzyl)sulfamoyl-2,3,4-trifluorobenzene To a stirring solution comprised of b/s-4-methoxybenzylamine (2.5 g,
- Step c Preparation of 5-b/s-(4-methoxybenzyl)sulfamoyl-2-(2-chloro-4- iodophenylamino)-3,4-difluorobenzoic acid (PD 215729)
- a stirring solution comprised of 2-chloro-4-iodoaniline (0.53 g, 2.0x10 "3 mol) in tetrahydrofuran (10 ml) at -78 °C under a nitrogen atmosphere was added a solution comprised of 1.0 M lithium bis(trimethylsilyl)amide in tetrahydrofuran
- Step d Preparation of 5-b/s-(4-methoxybenzyl)sulfamoyl-2-(2-chloro-4- iodophenylamino)-N-cyclopropylmethoxy-3.4-difluorobenzamide (PD 218774)
- Step e Preparation of 2-(2-chloro-4-iodophenylamino)-N-cvclopropylmethoxy- 3.4-difluoro-5-sulfamoyl-benzamide (PD 219622)
- a reaction solution comprised of 5-b/ ' s-(4-methoxybenzyi)sulfamoyl-2-(2- chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide (0.1010 g, 1.266x10 "4 mol) in thfluoroacetic acid (4 ml) was stirred at ambient temperature for 24 hours.
- reaction mixture was stirred for 30 minutes, was concentrated in vacuo to a yellow oil, and was crystallized from methanol to afford 0.35 g of the off-white amorphous intermediate; 46 % yield; the intermediate was dissolved in thfluoroacetic acid (10 ml) and was stirred at ambient temperature for 16 hours.
- Step a Preparation of 2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-5- dimethylsulfamoyl-benzoic acid (PD 224339)
- a lithium 2-chloro-4-iodoanilide suspension formed by adding a 1.0 M solution of lithium /s(trimethylsilyl)amide solution (7.2 ml, 7.2x10 "3 mol) to a solution comprised of 2-chloro-4-iodoaniline (0.94 g, 3.63x10 "3 mol) in tetrahydrofuran (15 ml) at -78 °C was added via canuia to the lithium 5-dimethylsulfamoyl-2,3,4- trifluorobenzoate suspension. The cold bath was removed and the reaction mixture was stirred for one hour. The mixture was concentrated in vacuo to a crude solid.
- Step b Preparation of 2-(2-chloro-4-iodo-phenylamino)-N-cvclopropylmethoxy- 3,4-difluoro-5-dimethylsulfamoyl-benzamide
- Step a Preparation of 3,4-difluoro-5-dimethylsulfamoyl-2-(4-iodo-2-methyl- phenylaminoVbenzoic acid (PD 224340)
- Step b Preparation of N-cvclopropylmethoxy-3.4-difluoro-5-dimethylsulfamoyl-2- (4-iodo-2-methyl-phenylamino)-benzamide Same procedure and same scale as Example 4, Step b, except the product was purified by recrystallization from absolute ethanol to afford 0.1718 g of the pale yellow microcrystalline product; 28 % yield; mp 171-172 °C; 1 H-NMR
- Step b Preparation of 4-methyl-3-nitro-benzene-N,N-dimethylsulfonamide
- a gently stirring solution comprised of 1 molar equivalent of fuming nitric acid in excess concentrated sulfuric acid is added 1 molar equivalent of 4- methyl-benzene-N,N-dimethylsulfonamide in increments.
- the mixture is stirred for one hour and then poured over chilled water.
- the mixture is extracted with a suitable solvent like diethyl ether or dichloromethane.
- the organic phase is dried over a suitable drying agent like magnesium sulfate and concentrated in vacuo to afford a crude product which may be purified by normal methods such as chromatography or crystallization from a solvent like chloroform or heptane.
- Step c Preparation of 3-amino-4-methyl-benzene-N,N-dimethylsulfonamide
- the compound 4-methyl-3-nitro-benzene-N,N-dimethylsulfonamide is dissolved in ethanol.
- a catalyst like Raney nickel is added and the mixture hydrogenated in a shaker. The catalyst is removed by filtration. The solvent is removed in vacuo to give a product which may be purified if necessary by chromatography or crystallization from an appropriate solvent like chloroform or heptane-ethyl acetate.
- Step d Preparation of 3-fluoro-4-methyl-benzene-N,N-dimethylsulfonamide
- the compound 3-amino-4-methyl-benzene-N,N-dimethylsulfonamide is diazotized with an alkyl nitrite like terf-butyl nitrite under anhydrous conditions in a non-reactive solvent like tetrahydrofuran or dichloromethane.
- the intermediate diazonium species is then treated with pyridinium fluoride to give the product, which may be purified by chromatography or crystallization.
- Step e Preparation of 4-dimethylsulfamoyl-2-fluoro-benzoic acid
- a mixture comprised of 3-fluoro-4-methyl-benzene-N,N- dimethylsulfonamide and potassium permanganate (2.2 molar equivalents) in water is brought to reflux for four hours.
- the reaction mixture is filtered through celite.
- the filtrate is treated with activated carbon and refiltered through fresh celite.
- the second filtrate is acidified with concentrated hydrochloric acid to pH 0.
- the mixture is allowed to cool and is extracted with diethyl ether.
- the organic phase is dried over a drying agent like magnesium sulfate and is concentrated in vacuo.
- the product may be purified by recrystallization from an appropriate solvent like ethanol or chloroform.
- Step f Preparation of 2-(2-chloro-4-iodo-phenylamino)-4-dimethylsulfamoyl- benzoic acid
- Step g Preparation of 2-(2-chloro-4-iodo-phenylamino)-4-dimethylsulfamoyl- benzoic acid O-(tetrahvdro-2H-pyran-2-yl)-oxyamide
- Step h Preparation of 2-(2-chloro-4-iodo-phenylamino)-4-dimethylsulfamoyl-N- hvdroxy-benzamide
- the compound 2-(2-chloro-4-iodo-phenylamino)-4-dimethylsulfamoyl- benzoic acid O-(tetrahydro-2H-pyran-2-yl)-oxyamide is dissolved in an appropriate hydrogen chloride-saturated solvent like methanol or ethanol. Once homogeneous, the solution is concentrated in vacuo to give the desired product. The product may be triturated with an appropriate solvent like chloroform or dichloromethane if further purification is necessary.
- EXAMPLE 8 Cascade assay for inhibitors of the MAP kinase pathway Incorporation of 32 P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase fusion protein containing p45MEK (GST-MEK).
- GST-MAPK glutathione S-transferase fusion protein containing p44MAP kinase
- GST-MEK glutathione S-transferase fusion protein containing p45MEK
- the assay solution contains 20 mM HEPES, pH 7.4, 10 mM MgCI 2 , 1 mM MnCI 2 , 1 mM EGTA, 50, ⁇ M [ ⁇ - 32 P]ATP, 10 ⁇ g GST-MEK, 0.5 ⁇ g GST-MAPK and 40 ⁇ g MBP in a final volume of 100 ⁇ L. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32 P retained on the filter mat is determined using a 120S Betaplate. Compounds are assessed at 10 ⁇ M for ability to inhibit incorporation of 32 P. To ascertain whether compounds are inhibiting GST-MEK or GST MAPK, two additional protocols are employed.
- Inhibitory activity can be confirmed in direct assays.
- MAP kinase 1 ⁇ g GST-MAPK is incubated with 40 ⁇ g MBP for 15 minutes at 30°C in a final volume of 50 ⁇ L containing 50 mM Tris (pH 7.5), 10 ⁇ M MgCI 2 , 2 ⁇ M EGTA, and 10 ⁇ M [ ⁇ - 32 P]ATP.
- the reaction is stopped by addition of Laemmli SDS sample buffer and phosphorylated MBP resolved by electrophoresis on a 10% polyacrylamide gel. Radioactivity incorporated into MBP is determined by both autoradiography, and scintillation counting of excised bands.
- the reaction is stopped by addition of Laemmli SDS sample buffer.
- Phosphorylated GST-MAPK-KA is resolved by electrophoresis on a 10% polyacrylamide gel. Radioactivity incorporated into GST-MAPK-KA is determined by autoradiography, and subsequent scintillation counting of excised bands.
- an artificially activated MEK containing serine to glutamate mutations at positions 218 and 222 (GST-MEK-2E) is used. When these two sites are phosphorylated, MEK activity is increased. Phosphorylation of these sites can be mimicked by mutation of the serine residues to glutamate.
- 5 ⁇ g GST-MEK-2E is incubated with 5 ⁇ g GST-MAPK-KA for 15 minutes at 30°C in the same reaction buffer as described above. Reactions are terminated and analyzed as above.
- EXAMPLE 13 Growth in soft-agar Cells are seeded into 35-mm dishes at 5 to 10,000 cells/dish using growth medium containing 0.3% agar. After chilling to solidify the agar, cells are transferred to a 37°C incubator. After 7 to 10 days' growth, visible colonies are manually enumerated with the aid of a dissecting microscope.
- Type II collagen-induced arthritis in mice is an experimental model of arthritis that has a number of pathologic, immunologic, and genetic features in common with rheumatoid arthritis.
- the disease is induced by immunization of DBA/1 mice with 100 ⁇ g type II collagen, which is a major component of joint cartilage, delivered intradermally in Freund's complete adjuvant.
- the disease susceptibility is regulated by the class II MHC gene locus, which is analogous to the association of rheumatoid arthritis with HLA-DR4.
- a progressive and inflammatory arthritis develops in the majority of mice immunized, characterized by paw width increases of up to 100%.
- a test compound is administered to mice in a range of amounts, such as 20, 60, 100, and 200 mg/kg body weight/day. The duration of the test can be several weeks to a few months, such as 40, 60, or 80 days.
- a clinical scoring index is used to assess disease progression from erythema and edema (stage 1), joint distortion (stage 2), to joint ankylosis (stage 3). The disease is variable in that it can affect one or all paws in an animal, resulting in a total possible score of 12 for each mouse. Histopathology of an arthritic joint reveals synovitis, pannus formation, and cartilage and bone erosions. All mouse strains that are susceptible to CIA are high antibody responders to type II collagen, and there is a marked cellular response to CM.
- EXAMPLE 15 SCW-induced monoarticular arthritis
- Rats receive 6 ⁇ g sonicated SCW [in 10 ⁇ l Dulbecco's PBS (DPBS)] by an intraarticular injection into the right tibiotalar joint on day 0. On day 21, the DTH is initiated with 100 ⁇ g of SCW (250 ⁇ l) administered i.v.
- SCW 250 ⁇ l
- SCW twice daily (10 ml/kg volume) beginning 1 hr prior to reactivation with SCW.
- Compounds are administered in amounts between 10 and 500 mg/kg body weight/day, such as 20, 30, 60, 100, 200, and 300 mg/kg/day. Edema measurements are obtained by determining the baseline volumes of the sensitized hindpaw before reactivation on day 21 , and comparing them with volumes at subsequent time points such as day 22, 23, 24, and 25. Paw volume is determined by mercury plethysmography.
- the incision is spread open and down to the cartilage parallel to the head, and sufficiently wide to accommodate the appropriate tunneling for a rat or insertion tool for a mouse.
- a neonatal mouse or rat pup less than 60 hours old is anesthetized and cervically dislocated.
- the heart is removed from the chest, rinsed with saline, bisected longitudinally with a scalpel, and rinsed with sterile saline.
- the donor heart fragment is placed into the preformed tunnel with the insertion tool and air or residual fluid is gently expressed from the tunnel with light pressure. No suturing, adhesive bonding, bandaging, or treatment with antibiotics is required.
- Implants are examined at 10-20-fold magnification with a stereoscopic dissecting microscope without anesthesia. Recipients whose grafts are not visibly beating may be anesthetized and evaluated for the presence of electrical activity using Grass E-2 platinum subdermal pin microelectodes placed either in the pinna or directly into the graft and a tachograph. Implants can be examined 1-4 times a day for 10, 20, 30 or more days. The ability of a test compound to ameliorate symptoms of transplant rejection can be compared with a control compound such as cyclosporine, tacrolimus, or orally-administered lefluonomide.
- a control compound such as cyclosporine, tacrolimus, or orally-administered lefluonomide.
- mice Female C57BIJ6 mice are obtained from the Jackson Laboratory (Bar Harbor, ME). All animals are given food and water ad libitum. Mice are sensitized with a single i.p. injection of OVA (grade V, Sigma Chemical Company, St. Louis, MO) adsorbed to alum, (10 ⁇ g OVA + 9 mg alum in 200 ⁇ l saline) or vehicle control, (9 mg alum in 200 ⁇ l saline) on day 0. On day 14, the mice are challenged with a 12-minute inhalation of an aerosol consisting of 1.5% OVA (weight/volume) in saline produced by a nebulizer (small particle generator, model SPAG-2; ICN Pharmaceuticals, Costa Mesa, CA).
- OVA grade V
- vehicle control 9 mg alum in 200 ⁇ l saline
- mice are dosed with oral vehicle (0.5% hydroxypropylmethylcellulose / 0.25% TWEEN- 80), or a test compound at 10, 30, or 100 mg/kg in oral vehicle, 200 ⁇ l per mouse p.o. Dosing is performed once per day starting on day 7 or day 13, and extending through day 16. For determination of pulmonary eosinophilia, three days after the first
- mice are anesthetized with an i.p. injection of anesthetic (Ketamine/Acepromazine/Xylazine), and the tracheae is exposed and cannulated.
- anesthetic Ketamine/Acepromazine/Xylazine
- the lungs and upper airways are lavaged twice with 0.5 ml of cold PBS.
- a portion (200 ⁇ l) of the bronchoalveolar lavage (BAL) fluid is enumerated using a Coulter counter Model ZB1 (Coulter Electronics, Hialeah, FL).
- the remaining BAL fluid is then centrifuged at 300 x g for five minutes, and the cells are resuspended in 1 ml of HBSS (Gibco BRL) containing 0.5% fetal calf serum (HyClone) and 10 mM HEPES (Gibco BRL).
- the cell suspension is centrifuged in a cytospin (Shandon Southern Instruments, Sewickley, PA) and stained by Diff Quick (American Scientific Products, McGraw Park, IL) to differentiate BAL leukocytes into neutrophil, eosinophil, monocyte or lymphocyte subsets.
- the number of eosinophils in the BAL fluid is determined by multiplying the percentage of eosinophils by the total cell count.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69928286T DE69928286T2 (en) | 1999-01-13 | 1999-12-21 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
AT99966496T ATE309205T1 (en) | 1999-01-13 | 1999-12-21 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
JP2000593571A JP2002534498A (en) | 1999-01-13 | 1999-12-21 | Benzenesulfonamide derivatives and their use as MEK inhibitors |
AU22015/00A AU2201500A (en) | 1999-01-13 | 1999-12-21 | Benzenesulfonamide derivatives and their use as mek inhibitors |
BR9916885-5A BR9916885A (en) | 1999-01-13 | 1999-12-21 | Benzene sulfonamide derivatives and their use as mek inhibitors |
US09/869,639 US6440966B1 (en) | 1999-01-13 | 1999-12-21 | Benzenesulfonamide derivatives and their use as MEK inhibitors |
CA002349832A CA2349832A1 (en) | 1999-01-13 | 1999-12-21 | Benzenesulfonamide derivatives and their use as mek inhibitors |
EP99966496A EP1144371B1 (en) | 1999-01-13 | 1999-12-21 | Benzenesulphonamide derivatives and their use as mek inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11587499P | 1999-01-13 | 1999-01-13 | |
US12242299P | 1999-03-02 | 1999-03-02 | |
US60/115,874 | 1999-03-02 | ||
US60/122,422 | 1999-03-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/869,639 A-371-Of-International US6440966B1 (en) | 1999-01-13 | 1999-12-21 | Benzenesulfonamide derivatives and their use as MEK inhibitors |
US10/198,561 Division US6750217B2 (en) | 1999-01-13 | 2002-07-18 | Benzenesulfonamide derivatives and their use as MEK inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000042003A1 true WO2000042003A1 (en) | 2000-07-20 |
Family
ID=26813663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/030435 WO2000042003A1 (en) | 1999-01-13 | 1999-12-21 | Benzenesulfonamide derivatives and their use as mek inhibitors |
Country Status (10)
Country | Link |
---|---|
US (2) | US6440966B1 (en) |
EP (1) | EP1144371B1 (en) |
JP (1) | JP2002534498A (en) |
AT (1) | ATE309205T1 (en) |
AU (1) | AU2201500A (en) |
BR (1) | BR9916885A (en) |
CA (1) | CA2349832A1 (en) |
DE (1) | DE69928286T2 (en) |
ES (1) | ES2252996T3 (en) |
WO (1) | WO2000042003A1 (en) |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005393A2 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
DE10017480A1 (en) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Use of substances that act as MEK inhibitors for the manufacture of a medicament against DNA and RNA viruses |
EP1255544A1 (en) * | 2000-01-31 | 2002-11-13 | Magainin Pharmaceuticals, Inc. | Mucin synthesis inhibitors |
WO2003022277A1 (en) * | 2001-09-07 | 2003-03-20 | Bayer Healthcare Ag | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
US7060856B2 (en) | 2003-10-21 | 2006-06-13 | Warner-Lambert Company | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2007049820A1 (en) | 2005-10-28 | 2007-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
WO2007132867A1 (en) | 2006-05-15 | 2007-11-22 | Takeda Pharmaceutical Company Limited | Prophylactic and therapeutic agent for cancer |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
US7425637B2 (en) | 2002-03-13 | 2008-09-16 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7485643B2 (en) | 2003-11-19 | 2009-02-03 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2009071947A2 (en) | 2007-12-05 | 2009-06-11 | Lectus Therapeutics Limited | Potassium ion channel modulators & uses thereof |
US7674797B2 (en) | 2003-03-24 | 2010-03-09 | Axikin Pharmaceuticals, Inc. | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
EP2195656A2 (en) * | 2007-08-21 | 2010-06-16 | Senomyx, Inc. | Human t2r bitterness receptors and uses thereof |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US7759518B2 (en) | 2005-07-21 | 2010-07-20 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US7803839B2 (en) | 2005-10-07 | 2010-09-28 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7928109B2 (en) | 2007-04-18 | 2011-04-19 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
US8003651B2 (en) | 2006-07-06 | 2011-08-23 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
EP2361905A1 (en) | 2005-05-18 | 2011-08-31 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and methods of use thereof |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8101611B2 (en) | 2003-11-19 | 2012-01-24 | Array Biopharma Inc. | Substituted pyridazines inhibitors of MEK |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
CN102665418A (en) * | 2009-10-08 | 2012-09-12 | 葛兰素史密斯克莱有限责任公司 | Combination |
WO2012160130A1 (en) | 2011-05-25 | 2012-11-29 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8404725B2 (en) | 2008-08-04 | 2013-03-26 | Merck Patent Gmbh | Phenylamino isonicotinamide compounds |
US8445692B2 (en) | 2007-08-21 | 2013-05-21 | Senomyx Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
WO2013178581A1 (en) | 2012-05-31 | 2013-12-05 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
US8618097B2 (en) | 2007-07-05 | 2013-12-31 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8680114B2 (en) | 2003-11-21 | 2014-03-25 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
US8741894B2 (en) | 2010-03-17 | 2014-06-03 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide CCR3 antagonists |
US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
WO2015038704A1 (en) | 2013-09-11 | 2015-03-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Compositions for preparing cardiomyocytes |
EP2823826A3 (en) * | 2008-01-09 | 2015-03-25 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase IX |
US9150549B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
US9303040B2 (en) | 2006-07-06 | 2016-04-05 | Array Biopharma Inc. | Substituted piperazines as AKT inhibitors |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US9682082B2 (en) | 2011-04-01 | 2017-06-20 | Genentech, Inc. | Combinations of AKT and MEK inhibitor compounds, and methods of use |
US10246453B2 (en) | 2016-05-20 | 2019-04-02 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US11174268B2 (en) | 2016-12-09 | 2021-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compouds and their use as therapeutic agents |
EP3936121A1 (en) | 2015-03-31 | 2022-01-12 | The General Hospital Corporation | Self assembling molecules for targeted drug delivery |
US11414396B2 (en) | 2012-10-12 | 2022-08-16 | Exelixis, Inc. | Process for making compounds for use in the treatment of cancer |
US11780862B2 (en) | 2022-03-04 | 2023-10-10 | Kinnate Biopharma Inc. | Inhibitors of MEK kinase |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070129282A1 (en) * | 1998-11-24 | 2007-06-07 | Ahlem Clarence N | Pharmaceutical treatments and compositions |
CA2669753C (en) * | 1999-09-30 | 2012-06-26 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
NZ518726A (en) * | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
PL378635A1 (en) * | 2002-03-13 | 2006-05-15 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
CN1964630A (en) | 2003-02-13 | 2007-05-16 | 耶希瓦大学艾伯塔·爱恩斯坦医学院 | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
EP1636183A1 (en) * | 2003-05-16 | 2006-03-22 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
TW200520745A (en) | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
DE102004028899B4 (en) * | 2004-06-09 | 2009-09-03 | Technische Universität Dresden | Use of a combination for the preventive and / or therapeutic treatment of bacterial infectious diseases or sepsis |
US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
WO2006084043A2 (en) * | 2005-02-02 | 2006-08-10 | The Uab Research Foundation | Novel chloride channel pore openers |
WO2007014011A2 (en) | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
KR20090111847A (en) * | 2007-01-19 | 2009-10-27 | 아디아 바이오사이언스즈 인크. | Inhibitors of mek |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
JP5881607B2 (en) * | 2009-10-08 | 2016-03-09 | ノバルティス アーゲー | combination |
BR112012008519A2 (en) * | 2009-10-12 | 2016-04-05 | Glaxosmithkline Llc | combination |
WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
EP2617415B1 (en) | 2010-09-16 | 2016-04-20 | Catholic Kwandong University Industry Foundation | Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells |
LT6064B (en) * | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
MX2015008471A (en) | 2012-12-27 | 2016-10-26 | Univ Drexel | Novel antiviral agents against hbv infection. |
US20160135446A1 (en) | 2013-06-13 | 2016-05-19 | Biomatrica, Inc. | Cell stabilization |
WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
WO2017100212A1 (en) | 2015-12-08 | 2017-06-15 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
WO1998037881A1 (en) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1163475C (en) | 1997-07-01 | 2004-08-25 | 沃尼尔·朗伯公司 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
-
1999
- 1999-12-21 ES ES99966496T patent/ES2252996T3/en not_active Expired - Lifetime
- 1999-12-21 AU AU22015/00A patent/AU2201500A/en not_active Abandoned
- 1999-12-21 US US09/869,639 patent/US6440966B1/en not_active Expired - Fee Related
- 1999-12-21 CA CA002349832A patent/CA2349832A1/en not_active Abandoned
- 1999-12-21 JP JP2000593571A patent/JP2002534498A/en active Pending
- 1999-12-21 AT AT99966496T patent/ATE309205T1/en not_active IP Right Cessation
- 1999-12-21 EP EP99966496A patent/EP1144371B1/en not_active Expired - Lifetime
- 1999-12-21 WO PCT/US1999/030435 patent/WO2000042003A1/en active IP Right Grant
- 1999-12-21 DE DE69928286T patent/DE69928286T2/en not_active Expired - Fee Related
- 1999-12-21 BR BR9916885-5A patent/BR9916885A/en not_active Application Discontinuation
-
2002
- 2002-07-18 US US10/198,561 patent/US6750217B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
WO1998037881A1 (en) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005393A3 (en) * | 1999-07-16 | 2001-05-10 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
WO2001005393A2 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
EP1255544A1 (en) * | 2000-01-31 | 2002-11-13 | Magainin Pharmaceuticals, Inc. | Mucin synthesis inhibitors |
EP1255544A4 (en) * | 2000-01-31 | 2005-02-02 | Genaera Corp | Mucin synthesis inhibitors |
US7504409B2 (en) | 2000-01-31 | 2009-03-17 | Genaera Corporation | Mucin synthesis inhibitors |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
DE10017480A1 (en) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Use of substances that act as MEK inhibitors for the manufacture of a medicament against DNA and RNA viruses |
EP1849469A1 (en) * | 2001-09-07 | 2007-10-31 | Actimis Pharmaceuticals, Inc., | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
WO2003022277A1 (en) * | 2001-09-07 | 2003-03-20 | Bayer Healthcare Ag | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
US7700586B2 (en) | 2001-09-07 | 2010-04-20 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
US8242118B2 (en) * | 2001-09-07 | 2012-08-14 | Axikin Pharmaceuticals Inc. | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders |
EP2130536A1 (en) | 2002-03-13 | 2009-12-09 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
EP2130537A1 (en) | 2002-03-13 | 2009-12-09 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
EP3000810A1 (en) | 2002-03-13 | 2016-03-30 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivative as mek inhibitor |
US7425637B2 (en) | 2002-03-13 | 2008-09-16 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US8193229B2 (en) | 2002-03-13 | 2012-06-05 | Array Biopharma Inc. | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7973170B2 (en) | 2002-03-13 | 2011-07-05 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US8003805B2 (en) | 2002-03-13 | 2011-08-23 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US8193230B2 (en) | 2002-03-13 | 2012-06-05 | Array Biopharma Inc. | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US8193231B2 (en) | 2002-03-13 | 2012-06-05 | Array Biopharma Inc. | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US8178693B2 (en) | 2002-03-13 | 2012-05-15 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US8513293B2 (en) | 2002-03-13 | 2013-08-20 | Array Biopharma Inc. | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
EP2275102A1 (en) | 2002-03-13 | 2011-01-19 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7674797B2 (en) | 2003-03-24 | 2010-03-09 | Axikin Pharmaceuticals, Inc. | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
US9206186B2 (en) | 2003-03-24 | 2015-12-08 | Axikin Pharmaceuticals, Inc. | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7511058B2 (en) | 2003-09-03 | 2009-03-31 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7230099B2 (en) | 2003-09-03 | 2007-06-12 | Array Biopharma, Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7060856B2 (en) | 2003-10-21 | 2006-06-13 | Warner-Lambert Company | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
US7772234B2 (en) | 2003-11-19 | 2010-08-10 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US8101611B2 (en) | 2003-11-19 | 2012-01-24 | Array Biopharma Inc. | Substituted pyridazines inhibitors of MEK |
EP2251327A2 (en) | 2003-11-19 | 2010-11-17 | Array Biopharma, Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US8268852B2 (en) | 2003-11-19 | 2012-09-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US8211920B2 (en) | 2003-11-19 | 2012-07-03 | Array Biopharma Inc. | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof |
US7598383B2 (en) | 2003-11-19 | 2009-10-06 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7485643B2 (en) | 2003-11-19 | 2009-02-03 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US8431574B2 (en) | 2003-11-19 | 2013-04-30 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7576072B2 (en) | 2003-11-19 | 2009-08-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US8680114B2 (en) | 2003-11-21 | 2014-03-25 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
US8524911B2 (en) | 2004-10-20 | 2013-09-03 | Merck Serono Sa | 3-arylamino pyridine derivatives |
US8841459B2 (en) | 2004-10-20 | 2014-09-23 | Merck Serono Sa | 3-arylamino pyridine derivatives |
US8198457B2 (en) | 2004-10-20 | 2012-06-12 | Merck Serono S.A. | 3-arylamino pyridine derivatives |
US8299076B2 (en) | 2005-05-18 | 2012-10-30 | Array Biopharma Inc. | Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide |
EP2361905A1 (en) | 2005-05-18 | 2011-08-31 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and methods of use thereof |
EP2364973A1 (en) | 2005-05-18 | 2011-09-14 | Array Biopharma, Inc. | Heterocyclic inhibitors of MEK and Methods of use thereof |
US8829052B2 (en) | 2005-07-21 | 2014-09-09 | Ardea Biosciences, Inc. | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US7759518B2 (en) | 2005-07-21 | 2010-07-20 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US7915250B2 (en) | 2005-10-07 | 2011-03-29 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7803839B2 (en) | 2005-10-07 | 2010-09-28 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US8362002B2 (en) | 2005-10-07 | 2013-01-29 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US11597699B2 (en) | 2005-10-07 | 2023-03-07 | Exelixis, Inc. | MEK inhibitors and methods of their use |
WO2007049820A1 (en) | 2005-10-28 | 2007-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
WO2007132867A1 (en) | 2006-05-15 | 2007-11-22 | Takeda Pharmaceutical Company Limited | Prophylactic and therapeutic agent for cancer |
US8846681B2 (en) | 2006-07-06 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8853199B2 (en) | 2006-07-06 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
US9303040B2 (en) | 2006-07-06 | 2016-04-05 | Array Biopharma Inc. | Substituted piperazines as AKT inhibitors |
US8003651B2 (en) | 2006-07-06 | 2011-08-23 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US9359340B2 (en) | 2006-07-06 | 2016-06-07 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
US8247411B2 (en) | 2007-04-18 | 2012-08-21 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US10450297B2 (en) | 2007-04-18 | 2019-10-22 | Pfizer, Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US7928109B2 (en) | 2007-04-18 | 2011-04-19 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8440822B2 (en) | 2007-04-18 | 2013-05-14 | Michael Joseph Luzzio | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US8618097B2 (en) | 2007-07-05 | 2013-12-31 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8445692B2 (en) | 2007-08-21 | 2013-05-21 | Senomyx Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
US8148544B2 (en) | 2007-08-21 | 2012-04-03 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and methods of making same |
EP2195656A4 (en) * | 2007-08-21 | 2011-10-19 | Senomyx Inc | Human t2r bitterness receptors and uses thereof |
US9247759B2 (en) | 2007-08-21 | 2016-02-02 | Senomyx, Inc. | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof |
EP2195656A2 (en) * | 2007-08-21 | 2010-06-16 | Senomyx, Inc. | Human t2r bitterness receptors and uses thereof |
US8466201B2 (en) | 2007-12-05 | 2013-06-18 | Ramot At Tel-Aviv University Ltd. | Potassium ion channel modulators and uses thereof |
WO2009071947A2 (en) | 2007-12-05 | 2009-06-11 | Lectus Therapeutics Limited | Potassium ion channel modulators & uses thereof |
WO2009071947A3 (en) * | 2007-12-05 | 2010-03-11 | Lectus Therapeutics Limited | Potassium ion channel modulators and uses thereof |
EP2823826A3 (en) * | 2008-01-09 | 2015-03-25 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase IX |
US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8404725B2 (en) | 2008-08-04 | 2013-03-26 | Merck Patent Gmbh | Phenylamino isonicotinamide compounds |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
CN102665418A (en) * | 2009-10-08 | 2012-09-12 | 葛兰素史密斯克莱有限责任公司 | Combination |
CN102665418B (en) * | 2009-10-08 | 2014-10-29 | 葛兰素史密斯克莱有限责任公司 | combination |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8637246B2 (en) | 2010-02-25 | 2014-01-28 | Dana-Farber Cancer Institute, Inc. | BRAF mutations conferring resistance to BRAF inhibitors |
US9279144B2 (en) | 2010-02-25 | 2016-03-08 | Dana-Farber Cancer Institute, Inc. | Screening method for BRAF inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US8741894B2 (en) | 2010-03-17 | 2014-06-03 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide CCR3 antagonists |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
US9150548B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use |
US9346789B2 (en) | 2011-04-01 | 2016-05-24 | Genentech, Inc. | Combinations of AKT inhibitor compounds and abiraterone, and methods of use |
US9150549B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
US9717730B2 (en) | 2011-04-01 | 2017-08-01 | Genentech, Inc. | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use |
US10092567B2 (en) | 2011-04-01 | 2018-10-09 | Genentech, Inc. | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use |
US9610289B2 (en) | 2011-04-01 | 2017-04-04 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
US9682082B2 (en) | 2011-04-01 | 2017-06-20 | Genentech, Inc. | Combinations of AKT and MEK inhibitor compounds, and methods of use |
WO2012160130A1 (en) | 2011-05-25 | 2012-11-29 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
US9833439B2 (en) | 2011-05-25 | 2017-12-05 | Universite Paris Descartes | ERK inhibitors for use in treating spinal muscular atrophy |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
WO2013178581A1 (en) | 2012-05-31 | 2013-12-05 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
US11414396B2 (en) | 2012-10-12 | 2022-08-16 | Exelixis, Inc. | Process for making compounds for use in the treatment of cancer |
WO2015038704A1 (en) | 2013-09-11 | 2015-03-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Compositions for preparing cardiomyocytes |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
EP3936121A1 (en) | 2015-03-31 | 2022-01-12 | The General Hospital Corporation | Self assembling molecules for targeted drug delivery |
US10246453B2 (en) | 2016-05-20 | 2019-04-02 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US10815229B1 (en) | 2016-05-20 | 2020-10-27 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US10662184B2 (en) | 2016-05-20 | 2020-05-26 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US11299490B2 (en) | 2016-05-20 | 2022-04-12 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US11174268B2 (en) | 2016-12-09 | 2021-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compouds and their use as therapeutic agents |
US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US11325902B2 (en) | 2018-06-13 | 2022-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
US11639351B2 (en) | 2018-08-31 | 2023-05-02 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11780862B2 (en) | 2022-03-04 | 2023-10-10 | Kinnate Biopharma Inc. | Inhibitors of MEK kinase |
Also Published As
Publication number | Publication date |
---|---|
ATE309205T1 (en) | 2005-11-15 |
EP1144371A1 (en) | 2001-10-17 |
US6750217B2 (en) | 2004-06-15 |
DE69928286D1 (en) | 2005-12-15 |
CA2349832A1 (en) | 2000-07-20 |
BR9916885A (en) | 2001-11-20 |
DE69928286T2 (en) | 2006-07-13 |
AU2201500A (en) | 2000-08-01 |
JP2002534498A (en) | 2002-10-15 |
US20030092748A1 (en) | 2003-05-15 |
ES2252996T3 (en) | 2006-05-16 |
EP1144371B1 (en) | 2005-11-09 |
US6440966B1 (en) | 2002-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1144371B1 (en) | Benzenesulphonamide derivatives and their use as mek inhibitors | |
EP1144372B1 (en) | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors | |
EP1144385B1 (en) | Benzoheterocycles and their use as mek inhibitors | |
EP1150950A2 (en) | Anthranilic acid derivatives | |
EP1144362A1 (en) | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors | |
US6506798B1 (en) | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors | |
ES2208364T3 (en) | PROCEDURE TO TREAT CHRONIC PAIN USING MEK INHIBITORS. | |
EP1144394B1 (en) | 1-heterocycle substituted diarylamines | |
US7001905B2 (en) | Substituted diarylamines as MEK inhibitors | |
CA2403017A1 (en) | 5-amide substituted diarylamines as mex inhibitors | |
JP2000212141A (en) | Diarylamine | |
JP2000212157A (en) | Diarylamine | |
MXPA01004180A (en) | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors | |
ZA200109909B (en) | Method for treating chronic pain using MEK inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/004332 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2349832 Country of ref document: CA Ref country code: CA Ref document number: 2349832 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999966496 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09869639 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 593571 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1999966496 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999966496 Country of ref document: EP |